Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: three case reports.
We used insulin pump therapy in three patients (two males and one female; age 5.5, 21 and 28.2 years, respectively) with CFRD and we reported the experience of 2 years of follow-up. In all the patients during the CSII treatment, the annual mean level of HbA1c reduced and the annual mean level of BMI increased, respected, the year before starting the CSII (in MDI treatment with 4 injections/day). The insulin requirements decreased during the CSII treatment and respected MDI treatment. During the CSII treatment, none of the patients exhibited episodes of DKA or severe hypoglycaemia. Only two episodes of lipohypertrophy and a slight local cutaneous inflammation were reported.


CONCLUSIONS
The use of CSII in our patients with CFRD improves the metabolic control of diabetes and the nutritional status with no concomitant problems related to this treatment.
Sulli
Nicoletta
N
Department of Pediatric, Diabetes Center, University of Rome La Sapienza, Policlinico Umberto I, Viale Regina Elena 324, 00161 Rome, Italy.
Bertasi
Serenella
S
Zullo
Sabina
S
Shashaj
Blegina
B
D000328:Adult; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications*; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D007332:Insulin Infusion Systems; D008297:Male; D009752:Nutritional Status; D016896:Treatment Outcome